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Background and Aim 
Glycated hemoglobin (HbA1c) plays a crucial role in the monitoring and diagnosis of diabetes. In Portugal 9,8% of the population  has diabetes 
(HbA1c ≥ 6,5%  or treatment with glucose-lowering medications)
1. Six sigma metrics combine bias, precision, and allowable total error (Tea), and 
can be used for assessing the quality of the analytic phase. 
The main objective of this study was to apply a linear regression model for long-term evaluation of the precision and inaccuracy, and apply the 
sigma metric to evaluate the performance of laboratories in HbA1c quantification
2. 
Methods 
The long term analytical coefficient of variation (LCVa), the total analytical bias and sigma were established.  
Participants were  selected concerning laboratories  that participated in all surveys. The assessment did not take into account the equipment used 
by each participant. The variables introduced to define the long-term performance in this model were the LCVa and total analytical Bias obtained by 
comparing the laboratory individual results with the consensus mean of each round, after outliers exclusion. The sigma value was calculate using 
the Tea obtained in the minimums analytical performance goals based on the biological variation3,4. A linear regression model was applied to 
quantitative HbA1c results, of twelve EDTA blood samples with different HbA1c concentrations, to evaluate the long-term analytical performance and 
the sigma value of twenty one participants in the period of 2014 to 2016 that participate in the PNAEQ (External Quality Assessment Program). 
Results are expressed in IFCC units (mmol/mol). Four laboratories were excluded from the analysis (outliers). We evaluate also the number of 
laboratories that fulfill the minimum analytical performance goals based on the biological variation (CVa and Bias).  
Results 
The consensus values, interlaboratory CV and number of outliers for the 12 surveys/samples used in the study are represented in table 1. The 
median LCVa was 2,4% (range 1,3%-5,2%), the median Total Bias was 2,0% (range 0,2%-6,0%) and median sigma value was 1,7 (range 0,1-4,6) 
(table 2).  
The LCVa was less than 0,58 times the total biological variation (diagnostic testing) for 94 % laboratories and was less than 0,75 times the within 
biological variation (monitoring testing) in 29 % of the laboratories. Sixty five percent of the laboratories had a total bias less than 0,375 of the total 
biological variation (table 3). 
Forty one percent of the laboratories had a sigma value less than 2,0 and fifty nine percent had a sigma value equal or higher than 2,0, when 
evaluated with an allowable total error of 6,72%, based on minimum performance criterions of the biological variation (figure 1).  
Table 1: Consensus values, interlaboratory CV and number of 
outliers for the 12 surveys/samples used in the study 
Survey/ 
Sample  
No. of 
participant
s  
Consensus 
value, 
mmol/mol 
CV, %  
No. of 
outliers  
2116 38 99,7 4,72 1 
2216 38 34,7 6,33 2 
1116 44 59,6 4,16 2 
3216 37 37,9 4,95 2 
3115 52 95,7 5,37 1 
3215 51 33,9 6,13 2 
2115 55 101,1 4,38 1 
3116 37 94,6 7,51 2 
1115 51 82,7 4,37 2 
1215 51 60,7 4,72 1 
3114 53 85,0 2,62 12 
3214 53 31,0 2,39 11 
Table 2: Descriptive analysis of Long-term analytical CV, total Bias and 
Sigma value results  
   LCVa, %  Bias,  %  
Sigma 
(Tea=6,72%) 
Median  2,4 2,0 1,7 
Range  1,3-5,2 0,2-6,0 0,1-4,6 
n  17 17 17 
Table 3: “Minimum” performance goals and quality specifications for Glycated Haemoglobin. [CVt – Total 
biologic variation; Cvi – Within subject variation; CVb – Between suject variation] and percentage of 
laboratories in the study within the minimum performance goals 
   
“Minimum” Performance 
goals  
Quality 
specifications  Laboratories within the 
Minimum performance 
goals, %  HbA1c mmol/L HbA1c mmol/L 
Imprecision 
(Diagnostic) %  
0,58 CVt ( √(CVi2   + CVb2)) 5,09 94 
Imprecision 
(Monitoring ) %  
0,75 CVb within 2,08 29 
Total Bias%  0,375 √(CVi2   + CVb2) 3.29 65 
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Sigma   
% of laboratories 
Sigma < 2 41 
Sigma ≥ 2 59 
Figure 1: : Histogram of the individual  Sigma for Glycated haemoglobin for the 17 
laboratories included in the study and the percentage of laboratories with sigma 
value inferior to 2 and superior or equal to 2. 
 
As reflected by the results the overall performance needs to be improved. Despite 94% of the laboratories evaluated accomplished the minimum 
quality specifications for imprecision (diagnostic), only 65% and 29% of the laboratories met the quality specifications for Total Bias and imprecision 
(monitoring) respectively. The median sigma (1.7) was less than 2 and only 59% of the laboratories had a sigma greater than or equal to 2. 
It is a responsibility of clinical laboratories to continuously monitor the performance of the methods in use, both by the implementation of proper 
internal quality control, checking the daily alignment of the analytical system and evaluating the assay long-term imprecision by the participation in 
appropriately organized external quality assessment schemes. 
Assessment of the quality on the sigma scale has the advantage of providing evidence of global laboratory performance taking into account random 
and systematic errors, and should be used for identifying and prioritizing improvements that are needed in the analytical quality of laboratory 
examinations. 
Conclusion 
